Login to Your Account

Rib-X, Sanofi Ink Potential $760M Pact to Develop RX-04

By Marie Powers

Thursday, July 7, 2011
Rib-X Pharmaceuticals Inc. hooked a big fish for its first partnership, inking an exclusive worldwide research collaboration and licensing option with Sanofi SA, of Paris, for antibiotics resulting from its RX-04 program for the treatment of resistant Gram-positive and resistant Gram-negative pathogens.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription